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Standard antimicrobial susceptibility tests used to determine bacterial susceptibility to
antibiotics are growth dependent and time consuming. The long incubation time required
for standard tests may render susceptibility results irrelevant, particularly for patients
infected with lethal bacteria that are slow growing on agar but progress rapidly in
vivo, such as Yersinia pestis. Here, we present an alternative approach for the rapid
determination of antimicrobial susceptibility, based on the quantification of the changes
in the expression levels of specific marker genes following exposure to growth-inhibiting
concentrations of the antibiotic, using Y. pestis and ciprofloxacin as a model. The
marker genes were identified by transcriptomic DNA microarray analysis of the virulent
Y. pestis Kimberley53 strain after exposure to specific concentrations of ciprofloxacin for
various time periods. We identified several marker genes that were induced following
exposure to growth-inhibitory concentrations of ciprofloxacin, and we confirmed the
marker expression profiles at additional ciprofloxacin concentrations using quantitative
RT-PCR. Eleven candidate marker transcripts were identified, of which four mRNA
markers were selected for a rapid quantitative RT-PCR susceptibility test that correctly
determined the Minimal Inhibitory Concentration (MIC) values and the categories of
susceptibility of several Y. pestis strains and isolates harboring various ciprofloxacin MIC
values. The novel molecular susceptibility test requires just 2 h of antibiotic exposure in a
7-h overall test time, in contrast to the 24 h of antibiotic exposure required for a standard
microdilution test.
Keywords: antibiotics, rapid AST, Y. pestis, qRT-PCR, molecular testing, ciprofloxacin, minimal inhibitory
concentration (MIC), RNA expression
INTRODUCTION
Rapid determination of the antibiotic susceptibility of pathogenic bacteria is required to assure
proper treatment of the bacterial infection. Bacterial susceptibility is determined by standard
antimicrobial susceptibility tests (ASTs) performed according to Clinical and Laboratory Standards
Institute guidelines (CLSI, 2015). ASTs are growth-dependent assays in which bacterial growth in
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the presence and absence of the relevant antibiotic is compared.
Preliminary bacterial isolation, enrichment and identification
steps are required. Thus, susceptibility determination is a time-
consuming procedure that may delay appropriate antibiotic
treatment for the patient, and a novel rapid AST is needed. Rapid
ASTs are particularly important for fatal pathogenic bacteria that
grow slowly in vitro but rapidly in vivo, such as Yersinia pestis.
Y. pestis, a Gram-negative bacterium, is the etiological agent
of plague, a severe and rapidly progressing disease characterized
by a high mortality rate (40–60% for the bubonic, 30–50% for
the septicemic, and 100% for the pneumonic forms of plague)
if not treated with proper antibiotics within 18–24 h after the
onset of symptoms (Pollitzer, 1960; Inglesby et al., 2000). Plague
has caused millions of deaths in three world pandemics, and
local outbreaks in endemic areas (Gage and Kosoy, 2005; Butler,
2013) or potential intentional dissemination in a bioterror
event remain concerns. Due to its rapid disease progression
and person-to-person transmission (Inglesby et al., 2000),
Y. pestis is classified by the Centers for Disease Control and
Prevention (CDC) as a Tier 1 Select Agent. To prevent morbidity
and mortality, rapid identification of the microbial agent and
its susceptibility to recommended antibiotics is needed. The
recommended antibiotics for post-exposure prophylaxis of
Y. pestis are ciprofloxacin, doxycycline and, as an alternative,
chloramphenicol, whereas the recommended antibiotics for
treatment are streptomycin, gentamicin and, as alternatives,
levofloxacin, ciprofloxacin, doxycycline, moxifloxacin and
chloramphenicol (Inglesby et al., 2000; CDC, 20161). Most
naturally occurring Y. pestis strains are susceptible to the
recommended antibiotics; however, plasmid-mediated single
and multiple drug-resistant strains have been isolated from
infected patients (Galimand et al., 2006). To select appropriate
antibiotics for plague prophylaxis or treatment, a microdilution
test is recommended (CLSI, 2015). Y. pestis growth in liquid
is not significantly slower than other Gram-negative bacterial
pathogens; however, its growth on solid agar, which is required
for isolation, is considered slow. Therefore, the standard
procedure for a positive clinical sample usually requires 3 days
(including 2 days for the enrichment step on rich agar followed
by 24 h for the AST). Moreover, ASTs of environmental Y.
pestis samples (as in a bioterrorism attack) require an additional
isolation step of the sample on selective agar and thus require at
least 5 days (including 2 days for the isolation step, 2 days for
the enrichment step, and 24 h for the AST). Because death may
occur within a few hours of bacterial exposure and symptom
onset (Pollitzer, 1960; Dennis and Hughes, 1997), rapid ASTs are
urgently needed.
In recent years, different novel methods have been developed
to decrease the AST duration by reducing the time required
for either the preliminary isolation and enrichment steps or
the susceptibility determination step (reviewed by Pulido et al.,
2013; van Belkum and Dunne, 2013). For example, we have
developed a rapid susceptibility test for Y. pestis-positive blood
cultures that includes the direct isolation and enrichment of the
bacteria from the blood culture components using a vacutainer
1http://www.cdc.gov/plague/healthcare/clinicians.html
serum separation tube, followed by bacterial counting using
flow cytometry (Steinberger-Levy et al., 2007). Few of the
novel alternative methods [such as flow cytometry for live/dead
determination (Jepras et al., 1997)] enable the determination
of both the antibiotic minimal inhibitory concentration (MIC)
and category of susceptibility, and most other methods [such
as using MALDI-TOF-MS (Burckhardt and Zimmermann,
2011) or magnetic bead rotation (Kinnunen et al., 2012)]
determine only the category of susceptibility (reviewed by van
Belkum and Dunne, 2013). Determining the MIC value of
antibiotics and not only the susceptibility category is particularly
important in complicated cases, such as infected patients with
contraindications to the first-choice antibiotic, pregnant women,
children and strains whose sensitivity is close to the resistant
category break-point (intermediate category).
In the present study, we describe the development of a rapid
mRNA-based molecular AST using Y. pestis and ciprofloxacin as
our bacteria:antibiotic model combination. The molecular AST
is based on monitoring the changes in the expression of specific
mRNA transcripts (mRNA markers) induced by 2-h exposure to
ciprofloxacin.
Ciprofloxacin, the model antibiotic in the present study, is a
bactericidal fluoroquinolone. Fluoroquinolones inhibit bacterial
growth mainly by binding to DNA gyrase and topoisomerase IV
and thus preventing DNA synthesis and repair, resulting in DNA
damage and bacterial death (Redgrave et al., 2014). Exposure
of various bacteria to ciprofloxacin or other fluoroquinolones
induces common transcriptomic changes, such as induction of
genes belonging to the SOS response pathway, as well as changes
in mRNA transcripts that differ among studies (Gmuender et al.,
2001; Shaw et al., 2003; Kaldalu et al., 2004; Brazas and Hancock,
2005; Cirz et al., 2006, 2007). Moreover, the fold induction of
different genes varies among studies. These differences can be
attributed to the different experimental conditions used, such as
bacterial species, antibiotic concentrations, antibiotic exposure
time, inoculum size and growth medium. In addition, previous
transcriptomic analyses were not performed under standard
CLSI-recommended conditions.
Thus, to identify marker mRNA transcripts that are altered
upon Y. pestis exposure to inhibitory concentrations (1× MIC
and above) of ciprofloxacin, we conducted transcriptome
analysis using DNA microarray analysis. The exposure
experiments were performed under CLSI-recommended
conditions. Several mRNA transcripts that were induced or
repressed, depending on both exposure time and ciprofloxacin
concentration, were identified. Using 4 marker genes, we
developed a 7-h quantitative RT-PCR (qRT-PCR)-based AST
for the determination of Y. pestis susceptibility to ciprofloxacin.
The measured changes in transcription levels were translated
to the strain’s MIC value and the susceptibility category. The
molecular-derived MIC values were similar to those obtained
using the standard 24-h CLSI test. Our rapid molecular
AST was confirmed using the virulent Kimberley53 strain,
its non-virulent derivative Kimberley53pCD1−pPCP1−,
several Kimberley53pCD1−pPCP1− isolates with reduced
susceptibility toward ciprofloxacin and the EV76 vaccine
strain.
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MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Experiments were conducted using the virulent Y. pestis
strain Kimberley53 (Ben-Gurion and Hertman, 1958). An
in-house DNA sequencing analysis of this strain (which
harbors the 3 virulent plasmids: pMT1, pCD1, and pPCP1)
revealed 99.7% homology with the CO92 clinical strain (biovar
orientalis) and 100% identity in the sequences encoding
known virulent factors, including both chromosomal and
plasmidial factors. Kimberley53 has been shown to be virulent
in both pneumonic (Vagima et al., 2015) and bubonic
(Tidhar et al., 2009) mouse plague models, and its mouse
LD50 in those models resembles the CO92 MLD50 values.
In addition, we also used the plasmid-cured non-virulent
Kimberley53pCD1−pPCP1− derivative strain (Flashner et al.,
2004) or the vaccine strain EV76 (Ben-Gurion and Hertman,
1958). Experiments using the virulent strain were performed
using biosafety level 3 (BSL-3) containment and procedures.
Experiments conducted using the non-virulent strains, were
performed using biosafety level 2 (BSL-2) containment and
procedures.
Kimberley53pCD1−pPCP1− spontaneous mutants
with reduced susceptibility to ciprofloxacin were isolated
according to previously published reports (Lindler et al., 2001;
Udani and Levy, 2006; Louie et al., 2007a,b, 2011a,b). The
isolation was performed in compliance with Israeli law for
working with select agents, approved by the Institutional
“Recombinant DNA Experimental Usage Committee” and
performed according to specific Institutional “Biosafety
committee” guidelines for containment and working
procedures.
Bacteria were plated on brain-heart infusion agar (BHIA, BD)
or on BIN [a Y. pestis selective agar plate (Ber et al., 2003)].
Live counting of bacteria was performed by plating serial 10-
fold dilutions on BHIA, followed by incubation for 48 h. All
incubations were conducted at the optimal growth temperature
of 28◦C.
Standard Ciprofloxacin MIC Determination
ASTs were performed by standard microdilution test (CLSI,
2015) in a 96-well microplate (TPP) using an inoculum
containing 5 × 105–1 × 106 colony-forming units (CFUs)/ml
suspended in cation-adjusted Mueller-Hinton broth (MHB,
BBL). Ciprofloxacin (Ciproxin 200, Bayer) was serially diluted
two-fold in MHB to a final concentration in the range of 0.001–
16 µg/ml. Bacterial cultures were incubated for 24 h at 28◦C
in a plate reader (Sunrise or Infinite 200, TECAN), and the
optical density at 630 nm (OD630) was read at 1-h intervals.
The MIC value was defined after 24 h of growth as the lowest
ciprofloxacin concentration that reduced growth to less than 10%
of the OD630 of the no-antibiotic growth control. No growth was
verified by unaided visual inspection. Each assay was performed
with three independent experiments. The microdilution kinetic
curves represent the average absorbance of three well replicates
for each antibiotic concentration. The error bars represent the
standard deviation (SD).
Antibiotic Exposure
Y. pestis exposed to ciprofloxacin was prepared for either
transcriptomic DNA microarray analysis or molecular-based
AST by suspending BHIA- or BIN-plated (lawn with pinhead-
sized colonies) bacteria in MHB to OD660 = 0.1 (1–2 × 10
8
CFU/ml). The cultures were then diluted 1:200 in MHB to obtain
the standard CLSI-recommended inoculum of 5 × 105–1 × 106
CFU/ml (CLSI, 2015).
For the transcriptomic DNA microarray analysis, BHIA-
plated virulent Kimberley53 was suspended in MHB (in five
2-l Erlenmeyer flasks each containing 420 ml of standard
inoculum). The flasks were incubated with continuous shaking
at 150 rpm for 2 h for the adjustment of the culture to the
standard AST MHB medium. The cultures were then combined,
mixed and divided into five culture samples of 400 ml each.
Ciprofloxacin stock solutions (4 ml of 100×) were added to
four cultures to obtain final concentrations of 0.001, 0.016,
0.5, and 4 µg/ml, and the non-treated culture was used as
a growth control. Each of the five cultures was then further
divided into 4 × 100 ml in 0.5-l flasks (each flask represents
one exposure time point). Samples (0.5 ml) were taken for
microdilution AST (triplicates of 0.1 ml/well) to confirm the
standard MIC value (0.15 ml of the 0.016 µg/ml sample was
also diluted 1:1 to verify the partial inhibition of growth at
the sub-MIC concentration of 0.008 µg/ml; see Figure 2A).
The 0.5-l Erlenmeyer flasks were incubated with shaking at
150 rpm for either 20, 45, 90, or 120 min. At each time
point, samples were taken for both live counting and total
RNA extraction. For RNA extraction, 40 ml of the bacterial
suspension was centrifuged at 3200 × g for 15 min at 4◦C,
the supernatant was discarded, and the bacterial pellet was
frozen by liquid nitrogen and stored at −70◦C until RNA
extraction.
To prepare the inoculum for the molecular AST experiments,
bacteria were plated on BIN for 20–24 h. The inoculum was then
prepared and recovered for 2 h in MHB prior to ciprofloxacin
exposure as described above. The recovered cultures were
exposed to serial 2-fold dilutions of ciprofloxacin (in the range
of 0.002–16 µg/ml, as indicated in the figures) in MHB for 2
h in a sample volume of 0.5 ml in a 24-well flat bottom plate
(Costar 3524). The entire 0.5-ml well volume was used for RNA
extraction.
RNA Purification
Total RNA was extracted from bacterial pellets using the
RNeasy Mini kit (QIAGEN) according to the manufacturer’s
instructions. Residual DNA was removed by 15-min on-
column digestion using the RNase-free DNase kit (QIAGEN).
RNA samples were quantified using a NanoDrop ND-1000
spectrophotometer. For DNA microarray analysis, the quality
of the RNA samples was determined using an Agilent 2100
Bioanalyzer with the “Prokaryote Total RNA Nano” chip. The
RNA integrity number (RIN value) was determined for each
sample, and samples with RIN ≥ 9 were used for the DNA
microarray analysis. RNA samples were stored at −70◦C until
further use.
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Transcriptomic Microarray Analysis
Complementary RNA (cRNA) was produced from the RNA
samples and fluorescently labeled using the MessageAmpTM
II-Bacteria kit (Ambion) according to the manufacturer’s
instructions with either Cy3-CTP or Cy5-CTP (Perkin
Elmer) as the fluorescent label. Specific activity and cRNA
concentrations were determined using a NanoDrop ND-1000
spectrophotometer. The labeled samples were stored at −70◦C
until use. Dual-color DNA microarray hybridizations were
performed using a custom Agilent 8x15K slide containing probes
for the 4196 chromosomal and plasmidial Y. pestis CO92 genes
and pseudogenes [Accession no. NC_003143.1 NCBI; (Parkhill
et al., 2001)]. Hybridization and scanning were performed as
suggested by Agilent. The slides were scanned in the Agilent
DNA microarray scanner G2505B. Images were analyzed, and
data were extracted using the Agilent Feature Extraction (FE)
software (version 9.5.1.1), with linear and lowess normalization.
Statistical analysis was performed using the Limma (Linear
Models for Microarray Data) package from the Bioconductor
project (http://www.bioconductor.org). The processed signal
from the FE was read into Limma using the “read.maimages”
function. Background subtraction and lowess normalization were
performed for each array. Quantile normalization was applied
between arrays. The Benjamini-Hochberg false discovery rate
(FDR) was used to correct for multiple comparisons. The fold
change (FC) in each gene was calculated as the median FC value
measured for 3–5 different or replicated probes representing the
same gene. Each experiment comprised 4 samples representing 4
different ciprofloxacin concentrations and labeled with Cy3-CTP
that were co-hybridized with the growth control sample, which
was not exposed to ciprofloxacin and was labeled with Cy5-CTP.
Each slide was hybridized with samples originating from two
independent biological experiments representing the same
time point, performed with Cy3-Cy5 dye swap. The results are
available online (http://www.ncbi.nlm.nih.gov/geo/), GEO ID:
GSM2101145.
Quantitative Reverse Transcription-PCR
(qRT-PCR)
One-step qRT-PCR was performed in a 50-µl reaction mixture
containing 1 ng of total RNA as the template, 1 × buffer (0.5
M KCl, 0.1 M Tris-HCl, pH 8.8 [Bio-Rad], 1 µM SuperROX R©
[Biosearch Technologies]), 0.6 µM each primer, 0.3 µMTaqMan
probe, 0.2 mM dNTP, 3 mMMgCl2, 0.5 µl of Sensiscript reverse
transcriptase (QIAGEN), 2 U of Taq DNA polymerase (Promega)
and 0.4 µl of JumpStart Taq antibodies (Sigma). Gene-specific
primers and TaqMan probes (5′ 6-FAM; 3′ BHQ-1) were designed
based on the Y. pestis CO92 genomic sequence (NC_003143.1)
using Primer Express software (Table S1) and were ordered from
IDT (USA). qRT-PCR was performed in an Applied Biosystems
7500 real-time PCR system under the following conditions: 50◦C
for 30 min, 95◦C for 3 min, and 40 cycles of 94◦C for 15 s and
60◦C for 35 s. Negative template controls (NTCs) were used
for each primer/probe set to exclude nonspecific reactions. No
RT controls lacking Sensiscript reverse transcriptase were used
to confirm the effective removal of genomic DNA. A standard
curve was obtained for each primer/probe set using a serial
10-fold dilution of the growth control RNA sample (100–0.01
ng/reaction) to confirm the high dynamic range of their reaction
efficiency (results not shown).
The transcript FC, defined as the ratios of the mRNA
expression level in the ciprofloxacin-exposed sample to that
in the untreated sample, was calculated from the difference
between the Ct values (as obtained from the 7500 Real-time
PCR System Sequence Detection Software) of the ciprofloxacin-
exposed samples (Ct treatment) and the Ct value of the untreated
control sample (Ct control) using the equation: FC = 2
−1Ct
(1Ct= Ct treatment−Ct control).
For RNA extracted from 0.5-ml culture volumes (where RNA
concentrations were below the NanoDrop ND-1000 limit of
detection), equal volumes (5 µl) of total RNA were used for the
qRT-PCR, and the RNA concentrations were normalized using
a 16S rRNA primer set (Table S1) with a 1:1000 dilution of
the samples. FC was calculated according to the 11Ct method
(FC= 2−11Ct where11Ct=1Ct marker gene−1Ct16S RNA).
Representative outcomes from two independent experiments
are presented in the figures.
RESULTS
Identification of Ciprofloxacin Growth
Inhibitory-Responsive Genes by
Transcriptomic Screening
To develop a rapid qRT-PCR-based molecular AST, we searched
for candidate marker genes whose expression is altered in
correlation with the susceptibility level following short exposure
of Y. pestis to growth-inhibitory concentrations (≥1× MIC)
of ciprofloxacin (see schematic presentation in Figure 1). For
this purpose, an inoculum of 5 × 105–1 × 106 CFU/ml
of Y. pestis Kimberley53 virulent strain was obtained from
BHIA, suspended in MHB and incubated for 2 h at 28◦C
before exposure to different ciprofloxacin concentrations, for
different incubation times. Incubations were performed at the
FIGURE 1 | Schematic expression profile of a potential marker gene.
Hypothetical pattern of a potential marker gene expression profile following
exposure to an antibiotic at sub-MIC, MIC and above the MIC. Basal
expression of the tested marker gene in the growth control sample (black
dotted line) was defined as fold change (FC) = 1. Expression FC < threshold
value (red dashed line) was defined as a negative response (NR), whereas FC
≥ threshold value was defined as a positive response (PR) to the antibiotic.
The MIC derived from the molecular AST is the minimal antibiotic
concentration that leads to PR.
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optimal growth temperature of 28◦C. Because inoculum size
influences the MIC value (as illustrated for Y. pestis exposed to
ciprofloxacin in Figure S1), we used an inoculum concentration
of 5 × 105–1 × 106 CFU/ml as recommended by the CLSI
guidelines (CLSI, 2015). Cultures were exposed to ciprofloxacin
concentrations of 0.001, 0.016, 0.5, and 4 µg/ml (equivalent
to 1/16×, 1×, 31×, and 250× MIC, respectively). Samples of
the exposed cultures were withdrawn after 20, 45, 90, and 120
min. Total RNA purification and the transcriptomic profile
characterization were performed as described in the Materials
and Methods. The standard MIC value was determined in
parallel using the microdilution susceptibility test and the same
inoculum, culture media, and antibiotic solutions (Figure 2A).
In addition, live bacterial counting was performed to characterize
the ciprofloxacin-induced bacterial growth arrest and cell death
and its correlation with the transcriptomic alterations following
2-h antibiotic exposure (Figure 2B).
Live CFU counting of a culture exposed to a sub-MIC
concentration of ciprofloxacin (0.001 µg/ml; 1/16× MIC) did
not reveal growth inhibition or cell death (Figure 2). In contrast,
exposure to 1× MIC (0.016 µg/ml) ciprofloxacin led to growth
arrest (Figure 2A), while exposure to the higher ciprofloxacin
concentrations of 0.5 and 4 µg/ml (31× and 250× MIC,
respectively) caused both growth arrest (Figure 2A) and a
rapid ∼3 log reduction of bacterial CFU counts (Figure 2B).
The survival curves of the 31× and 250×MIC-exposed bacteria
exhibited typical biphasic patterns, consistent with the rapid
killing of most cells by the fluoroquinolone and a persistent
subpopulation that can survive the bactericidal effect of the
antibiotic (Dörr et al., 2009).
The transcriptomic analysis of the 1× MIC ciprofloxacin-
exposed culture revealed changes in the expression (both up-
regulation and down-regulation by a FC ≥ 2) of 0, 3, 13, and 31
genes following 20, 45, 90, and 120min of ciprofloxacin exposure,
respectively (Table 1). However, only some of the genes (3, 7, and
13 for 45, 90, and 120min of ciprofloxacin exposure, respectively)
exhibited changes in expression levels following exposure to 1×
MIC as well as to 31× and 250× MIC. Because more candidate
marker genes and higher expression FC values were observed
following 2 h of exposure to 1×MIC ciprofloxacin compared to
FIGURE 2 | Standard microdilution test and survival curves of Y. pestis Kimberley53 exposed to ciprofloxacin. A culture of MHB-suspended Y. pestis
Kimberley53 was prepared from BHIA-plated bacteria to a standard inoculum size of 5 × 105–1 × 106 CFU/ml and incubated for 2 h at 28◦C with moderate agitation
(for adjustment of the culture from the BHIA to MHB growth medium) before performing the 24-h microdilution test. (A) The microdilution test was conducted in a
96-well microplate at the indicated ciprofloxacin concentrations, and the OD630 was measured hourly using a TECAN plate reader. (B) Survival analysis was
performed by BHIA plating of serial 10-fold dilutions of replicate samples at different time points after ciprofloxacin addition. The error bars represent the SD of 3
independent experiments.
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TABLE 1 | Transcriptomic microarray results for the 1× MIC responsive genesa.
Gene Idb Gene nameb Annotationb Median fold changed
45 min. 90 min. 120 min.
MIC fold MIC fold MIC fold
1x 31x 250x 1x 31x 250x 1x 31x 250x
In
d
u
c
e
d
g
e
n
e
s
YPO1105 recN DNA repair protein RecN 2.2 5.3 17.3 3.7 4.3 18.5 4.1 5.2 12.0
YPO3307 lexB RecA 2 6 15.4 2.9 4.6 12.7 3.1 4.8 11.7
YPO1436 sfiA Putative cell division inhibitor 2 2.7 2.1 2.7 3.5 2.2
YPO1231 pla2 Putative outer membrane-associated protease 3.1 5.3 61 4.6 10.6 58.7
YPO3306 oraA Putative regulatory protein 2.4 4.6 24.7 2.7 10.5 33.9
YPO1232 dinI Putative stress response protein 2.3 7.4 41 3.7 9.0 49.8
YPO0324 b4058 Excinuclease ABC subunit A 2 2.2 5.6 2.3 3.0 5.0
YPPCP1.05c pst Pesticin 3.1 2.2 5.1
YPO0518 dinA DNA polymerase II 2.4 2.9 2.6 2.5
YPO3231 dinP DNA-damage-inducible protein P 2.3 3 2.6 2.3 3.3
YPO3841 mutU DNA helicase II 2.2 2.5
YPO1586 dinI DNA-damage-inducible protein I 2.9 3.3 13.0
YPO1233 YPO1233 Putative prophage repressor protein 2.6 4.8 10.6
YPMT1.86Ac YPMT1.86A Hypothetical protein 2.5 4.1 7.1
YPO0314 b4043 LexA repressor 2.7 3.4 3.7
YPO3782 rumC Putative DNA recombination protein 2.3
YPO3901 ilvG Acetolactate synthase isozyme II large subunit 2.2
YPO4111 YPO4111 Putative periplasmic solute-binding protein 2.2
YPO3900 ilvM Acetolactate synthase isozyme II small subunit 2.2
YPO3899 ilvE Branched-chain amino acid aminotransferase 2.1
YPO0003 asnA Aspartate-ammonia ligase 2.1 2.1
YPO3914 sth Soluble pyridine nucleotide transhydrogenase 2.1
YPO4119 glmU UDP-N-acetylglucosamine pyrophosphorylase 2.0
YPO4110 YPO4110 ABC transporter permease 2.0
YPO3015 cysP Thiosulfate-binding protein 2.0
YPO3872 rep ATP-dependent DNA helicase Rep 2.0
R
e
p
re
ss
e
d
g
e
n
e
s YPO2140 YPO2140 Hypothetical phage protein −2.2
YPO1398 cspB Cold shock-like protein −2.7 −8.2 −12 −2.5 −7.4 −10.4
YPO2659 cspB Cold shock protein −2.1 −5.5 −10.7
YPO2711 rpoE RNA polymerase sigma E factor −2.0 −4.2
YPO2712 mclA Sigma E factor negative regulatory protein −2.0 −5.2
YPO1325 YPO1325 Putative membrane protein −2.2
aThe table lists genes that exhibited at least a 2-fold difference in expression and an adjusted p-value (FDR) < 0.05. Genes that were changed following exposure to 31× MIC and or
250× MIC but not following 1× MIC ciprofloxacin are not listed in the table.
bGene ID, gene name and annotation are based on Y. pestis CO92 data (NC 003141.1, Parkhill et al., 2001).
cPlasmidial gene (all other genes are chromosomal).
dThe median fold change color is scaled as follows:
> −2 to <2 2 to <4 4 to <10 ≥10
the other time points, we further developed the rapid molecular
susceptibility assay using a 2-h incubation period. After 2 h of
exposure, 11 genes were induced and 2 genes were repressed by
a FC > 2 in all of the three tested ciprofloxacin concentrations.
One of the 11 induced genes, YPMT1.86A, is plasmid encoded
and was excluded from further analysis because the plasmid
may not be present in all Y. pestis strains. Notably, 8 of the
10 chromosomal induced genes belong to the SOS response
gene family (recN, dinI [YPO1232], recA, oraA, dinI [YPO1586],
b4058, dinP, and b4043), which is known to be induced following
DNA damage caused by ciprofloxacin. Similar effects have been
reported following exposure of heterologous bacteria to various
fluoroquinolones (Gmuender et al., 2001; Shaw et al., 2003;
Kaldalu et al., 2004; Cirz et al., 2006, 2007).
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The DNA microarray screen results were validated by qRT-
PCR analysis of the 10 induced and the two repressed genes using
the same RNA samples that were used for the DNA microarray
analysis. For comparison, a gene identified as non-responsive in
the DNA microarray analysis (capR [YPO3155]) was included in
the qRT-PCR validation. Seven of the 10 induced chromosomal
genes (pla2, recN, dinI [YPO1232], recA, oraA, dinI [YPO1586]
and YPO1233) exhibited significant changes in expression using
both techniques (Figure S2 and Table 2). A good correlation
with the DNA microarray results was also observed for the
two repressed genes. The non-responsive gene, capR, displayed
some reduction in expression at the higher ciprofloxacin
concentrations in the qRT-PCR analysis, whichmay be attributed
to the different normalization processes of the two quantification
methods.
For use in a molecular AST, we chose to focus on
positive response monitoring of chromosomal genes;
thus, the 7 induced potential marker genes were selected
for further characterization in a microdilution test
format.
Characterization of the Expression Profile
of the Candidate Marker Genes in a
Microdilution Format
Microdilution is the standard 24-h incubation test recommended
by the CLSI for susceptibility determination of Y. pestis (CLSI,
2015). To shorten this AST, we developed a molecular AST
based on the standard microdilution format, which requires
only a 2 h ciprofloxacin-exposure period, followed by RNA
purification and qRT-PCR monitoring of the FC levels of
the marker genes. The assay was performed in adherence to
CLSI-recommended conditions to maximize the possibility of
obtaining MIC values that are similar (equal or within one
2-fold dilution) to the standard microdilution-derived MIC
values. The molecular AST-derived MIC was defined as the
minimal antibiotic concentration that causes changes in the
marker gene expression levels equal to or above a threshold
level (see schematic presentation in Figure 1). The threshold
values used in the molecular ASTs were determined by analyzing
results at 1× MIC from all of the exposure experiments using
different hypothetical threshold values (starting with a value of
2.0 with 0.1 increments). For eachmarker, we chose the threshold
value that maximized the correct MIC prediction for all tested
strains while giving preference to minimizing major errors that
lead to a lower molecular MIC prediction as compared to the
actual MIC result by standard microdilution. We hypothesized
that these threshold values could be used to determine
the MICs for Y. pestis strains with unknown susceptibility
levels.
We determined the standard MIC and the expression profile
of the candidate marker genes following Y. pestis Kimberley53
exposure to serial two-fold dilutions of ciprofloxacin, yielding
a range of antibiotic concentrations around the MIC (0.002–
0.5 µg/ml, representing 0.125×–31× MIC). The MIC value
of ciprofloxacin in the standard 24-h microdilution test for
Kimberley53 was 0.016µg/ml (Figure 3A). Exposure to sub-MIC
concentrations of ciprofloxacin (0.002–0.008 µg/ml, 0.125–0.5×
MIC, respectively) resulted in a slight reduction of the growth
rate compared to the growth control (Figure 3A). Monitoring
the changes in the candidate marker gene expression levels
revealed that 4 of the 7 candidate marker genes (recA, recN,
TABLE 2 | Comparison of the FCs of selected genes determined by transcriptomic microarray and qRT-PCR analysis.
MIC fold DNA microarray results* qRT-PCR results**
1x 31x 250x 1x 31x 250x
Induced genes pla2 [YPO1231] 4.6 10.6 58.7 4.4 9.1 157.4
recN [YPO1105] 4.1 5.2 12.0 3.3 2 4.7
dinI [YPO1232] 3.7 9.0 49.8 3.2 4.4 20.9
recA [YPO3307] 3.1 4.8 11.7 4.2 4.8 6.6
oraA [YPO3306] 2.7 10.5 34.0 2.6 2.9 16.2
dinI [YPO1586] 2.9 3.3 13.0 3.1 1.5 12.1
YPO1233 2.6 4.8 10.6 2.1 1.7 4.9
b4058 [YPO0324] 2.3 3.0 5.0 1.5 1.0 1.9
b4043 [YPO0314] 2.7 3.4 3.7 2.1 1.5 1.2
dinP [YPO3231] 2.6 2.3 3.3 1.8 0.8 1.0
Repressed genes cspB-like [YPO1398] −2.5 −7.4 −10.4 −2.8 −15 −23.8
cspB [YPO2659] −2.1 −5.5 −10.7 −1.9 −7 −21.5
Non-responsive gene capR [YPO3155] 1.0 1.0 1.0 −1.2 −2.9 −3.3
Median FC level: > −2 to <2 2 to <4 4 to <10 ≥10
*The DNA microarray values are derived from the 2-h exposure data in Table 1. The values represent the calculated median FC as described in the Materials and Methods. **The
qRT-PCR values represent the mean values as described in the Materials and Methods.
Frontiers in Microbiology | www.frontiersin.org 7 May 2016 | Volume 7 | Article 763
Steinberger-Levy et al. Rapid Molecular Antibiotic Susceptibility Test
FIGURE 3 | Ciprofloxacin-induced growth inhibition and changes in the expression levels of the candidate genes. BHIA-isolated colonies of Y. pestis
Kimberley53 were suspended in MHB to a standard inoculum size of 5 × 105 to 1 × 106 CFU/ml. The culture was incubated for 2 h of recovery at 28◦C followed by
exposure to 2-fold serial dilutions of ciprofloxacin (40 ml each) at a range of 0.002–0.5 µg/ml. (A) Samples of 100 µl were transferred (from the 40 ml
ciprofloxacin-exposed cultures) to a 96-well microplate. The optical density at 630 nm was recorded hourly for 24 h using a TECAN plate reader. The MIC value was
determined at the 24-h time point. The OD630 values are the average of 3 replicated wells. (B) Cultures (40 ml) exposed to different concentrations of ciprofloxacin for
2 h, were used for total RNA extraction, and 1 ng of RNA sample was analyzed by qRT-PCR. The black dotted line represents basal expression (FC = 1) in the growth
control sample, and the colored dashed lines represent the threshold values of the tested marker genes. The figure is representative of duplicate analyses.
pla2, and dinI [YPO1232]) were induced > 2-fold following
exposure to ciprofloxacin concentrations of 0.016 µg/ml (1×
MIC) and above. However, the bacteria also responded to
the sub-MIC concentrations with variable but correlated levels
of induction. These results emphasize the high sensitivity of
the molecular test, which monitors the direct and primary
effects of the antibiotic on the bacterial molecular response,
whereas the growth rate indicates the consequence of those
molecular alterations. For example, recA was induced 2-fold
following exposure to a sub-MIC concentration of 0.002 µg/ml
(0.125× MIC, Figure 3B). The induction was enhanced as
the ciprofloxacin concentration increased. A threshold value
of 7.5 was assigned for recA usage as a marker gene for 1×
MIC value identification. Another candidate gene, recN, was
induced∼2-fold following exposure to a sub-MIC concentration
of 0.004 µg/ml (0.25× MIC), and a threshold FC value of
3.2 was set for the 1× MIC value determination (Figure 3B).
Similarly, we determined the threshold values for pla2, which
was induced ∼2-fold upon exposure to 0.008 µg/ml (0.5×
MIC) ciprofloxacin, and a threshold of 3.2 was assigned
for the determination of the 1× MIC value (Figure 3B). A
threshold FC of 2.5 was assigned to dinI [YPO1232]. Thus,
four candidate genes, recA, recN, pla2 and dinI [YPO1232],
exhibited potential utility as marker genes, while the compiled
expression profile results disqualified the other potential
markers.
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TABLE 3 | Characterization of the reduced ciprofloxacin sensitivity of
non-virulent Kimberley53pCD1−pPCP1− derivatives.
Derivative # MIC value
(µg/ml)a
CLSI Category
of susceptibility
gyrA mutation
Kimberley53pCD1−
pPCP1−
0.016 Sensitive w.t.
#83 0.125 Sensitive D87G
#34 0.25 Sensitive D82N
#111 0.5 Non-S S83R
#66 1 Non-S S83I
#66-6 4 Non-S S83I
Non-S, non-sensitive.
aMIC values were determined using the standard microdilution susceptibility test.
Confirmation of the Molecular AST Using
Kimberley53pCD1−pPCP1− Derivatives
with Decreased Ciprofloxacin
Susceptibility
For the proof-of-concept of the qRT-PCR-based molecular
AST, we analyzed the gene expression profiles of various
non-virulent Y. pestis Kimberley53pCD1−pPCP1− derivatives
with different ciprofloxacin MIC values. The derivatives were
either ciprofloxacin sensitive (MIC ≤ 0.25 µg/ml) or non-
sensitive (MIC > 0.25 µg/ml), as defined by the ciprofloxacin
susceptibility category for Y. pestis (CLSI, 2015). Point mutations
in the quinolone resistance-determining region (QRDR) locus,
which is part of ciprofloxacin target encoding, the gyrA gene,
are known to be acquired following exposure to fluoroquinolones
and reduce the bacterial sensitivity to the antibiotic (Wiedemann
and Heisig, 1994; Redgrave et al., 2014). Therefore, we sequenced
the QRDR locus of these isolates. Several point mutations
were identified (Table 3), thus partially explaining the reduced
sensitivity of these derivatives to ciprofloxacin.
The expression profiles of the four potential marker
genes (recA, recN, pla2, and dinI [YPO1232]) in the non-
virulent Kimberley53pCD1−pPCP1− parental strain exposed to
ciprofloxacin, resembled those in the w.t. virulent Kimberley53
strain (compare Figure S3 with Figure 3B). The pla2 gene
was induced ∼4.5-fold in the parental strain exposed to 0.016
µg/ml ciprofloxacin (microdilution measured 1× MIC value),
representing an FC above the assigned threshold value (FC =
3.2), as required (Figure 4 and Figure S3). In contrast, isolates
#83 and #66-6, which have higher MIC values (0.125 and
4 µg/ml, respectively), exhibited no induction at that (0.016
µg/ml) concentration (Figure 4). However, exposure to higher
ciprofloxacin concentrations representing the isolates’ higher
MIC values caused induction near the threshold value and above.
The exposure of isolate #83–0.125 µg/ml ciprofloxacin (the MIC
value of this isolate), resulted in a lower level of induction
compared to the parental strain (FC = 2.1 vs. 4.7). Thus,
using a threshold value of 3.2 for pla2, determined previously,
led to a molecular MIC of 0.25 µg/ml compared to 0.125
µg/ml observed in the microdilution test. A two-fold difference
is acceptable because in the standard microdilution test, the
accepted MIC value for QC reference strains might be in the
FIGURE 4 | Expression of pla2 in non-virulent Y. pestis
Kimberley53pCD1−pPCP1− and its derivatives #83 and #66-6. The
expression profile of pla2 was determined in the non-virulent Y. pestis
Kimberley53pCD1−pPCP1− (parental strain) and its ciprofloxacin
reduced-susceptibility derivatives #83 and #66-6. Cultures were prepared
from bacteria grown overnight on BIN, suspended in MHB and incubated for 2
h followed by 2 h exposure to the required ciprofloxacin concentrations in a
0.5-ml culture volume in 24-well plates. RNA samples were purified and used
for qRT-PCR analysis using 16S rRNA as a reference for FC determination as
described in the Materials and Methods. The MIC value for each derivative
was also determined by a standard microdilution test performed using the
same cultures that were used for the molecular AST. The colored arrows
indicate the microdilution-measured MIC values of the bacterial derivatives.
The black dotted line represents basal expression (FC = 1) in the growth
control sample, and the green dashed line represents the threshold value
assigned to pla2 (FC = 3.2). The figure is representative of duplicate analyses.
FIGURE 5 | Expression pattern of dinI [YPO1232] in non-virulent
Y. pestis Kimberley53pCD1−pPCP1− and its derivatives #83 and #66-6.
The molecular AST was performed as described in Figure 4. The black dotted
line represents basal expression (FC = 1) in the growth control sample, and
the red dashed line represents the threshold value assigned to dinI [YPO1232]
(FC = 2.5). The figure is representative of duplicate analyses.
range of 1 to 2 two-fold dilutions (CLSI, 2015). The non-sensitive
isolate #66-6 (standard microdilution MIC= 4 µg/ml) exhibited
marker induction above the threshold only following exposure
to ciprofloxacin at its MIC value (Figure 4). Similar results were
obtained in the qRT-PCR-based AST using dinI [YPO1232]
(Figure 5).
The level of induction of an additional marker gene, recN,
in the different isolates exposed to 0.5×, 1×, and 2× MIC
ciprofloxacin was correlated with the isolate’s MIC value. The
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FIGURE 6 | Expression pattern of recN in non-virulent Y. pestis EV76
and Kimberley53pCD1pPCP1− and its derivatives. The molecular AST
was performed as described in Figure 4. For each derivative, the
corresponding MIC (as determined by the standard microdilution assay) is
given in parenthesis. The black dotted line represents basal expression (FC =
1) in the growth control sample, and the orange dashed line represents the
threshold value assigned to recN (FC = 3.2). The figure is representative of
duplicate analyses.
threshold of 3.2 enabled the determination of the 1×MIC values
of both the sensitive and the non-sensitive Y. pestis isolates
(Figure 6).
The ability of the qRT-PCR assay to determine the MIC value
was also tested with EV76, anotherY. pestis strain. The expression
pattern of the four potential marker genes (recA, recN, pla2,
and dinI [YPO1232]) was similar to the pattern observed for
Kimberley53 and its derivative (Figure S4 vs. Figure 3B and
Figure S3). Using the above-mentioned assigned thresholds for
recN and dinI [YPO1232]) enabled the determination of the
correct MIC value (microdilutionMIC= 0.031µg/ml). TheMIC
value determined using the threshold assigned for pla2 was 0.064
µg/ml (2× microdilution MIC), which is within an acceptable
range of the AST results. It should be noted that even though
the expression pattern of recA was similar to that of the other
marker genes, the previously assigned threshold for recA (7.5)
could not be used to define the MIC value for EV76 because its
expression level in this strain was lower than that in Kimberley53
and its derivative Kimberley53pCD1−pPCP1−. The threshold
value assigned for recA was high due to its high expression
level, i.e., in sub-MIC concentrations of 0.5× and 0.25× MIC,
in Kimberley53 and its derivative Kimberley53pCD1−pPCP1−
(Figure 3B and Figure S3), indicating that not only the threshold
level but also the pattern of the markers’ response should be
taken into consideration when predicting bacterial susceptibility.
In such cases, we could use the other 3 marker genes (recN, pla2,
and dinI [YPO1232]) for MIC determination and the expression
pattern of the fourth marker gene (recA) to strengthen the MIC
interpretation.
In this manuscript, we present a proof-of-concept for rapid
determination of antibiotic MIC value using a molecular
approach. However, validation of the assay should be done
by using additional Y. pestis strains, with different genetic
backgrounds and biovars. This will enable the recommendation
of valid threshold values for the candidate marker genes and the
determination of the minimal marker genes required for valid
MIC interpretation.
Our results indicate that the qRT-PCR AST based on
these mRNA markers has the potential to be used for the
rapid determination of the MIC values of ciprofloxacin for
Y. pestis.
DISCUSSION
Reducing the time required for ASTs is of significant importance,
particularly for patients infected with pathogenic bacteria that
grow slowly in vitro but can cause rapidly progressing fatal
disease, such as that caused by Y. pestis. In addition, the
emerging number of drug-resistant bacterial strains necessitates
the development of novel technologies for rapid ASTs (Pulido
et al., 2013; van Belkum and Dunne, 2013). Standard ASTs are
time consuming because they are based on bacterial growth in
the presence and absence of the tested antimicrobial agent in
liquid media or growth in antibiotic diffusion gradients, such as
the disk diffusion test or Etest methods (Jorgensen and Ferraro,
2009). In addition to the time required for incubation during
the antibiogram tests, a pure culture must first be obtained by
isolation and enrichment steps. These growth-dependent and
time-consuming steps are the bottleneck for standard ASTs and
prolong the overall process to several days and even weeks,
depending on the bacterial source and the growth rate of the
tested bacteria. Thus, the development of alternative rapid ASTs
is crucial.
Various alternative AST methods have been described in
recent years, including nucleic acid-based ASTs. These nucleic
acid-based ASTs are performed by determining either the
bacterial chromosomal DNA copy number using qPCR or
phage-specific mRNA transcript copy number using qRT-PCR
(Waldeisen et al., 2011; Mulvey et al., 2015). However, these
assays are still growth dependent and time consuming. PCR
methods to detect mutations or gene lesions responsible for the
acquisition of resistance have been used for various bacteria,
such as monitoring point mutations in gyrA responsible for
ciprofloxacin resistance in Y. pestis (Lindler and Fan, 2003).
However, this method is not reliable because only some
resistance-conferring genes are known. Moreover, the MIC value
cannot be determined because the correlation of the bacterial
genotype with the antibiotic susceptibility is not direct (van
Belkum and Dunne, 2013).
In the present article, we describe the development of a
rapid molecular AST that is based on quantifying the FC of
specific mRNA marker expression following antibiotic exposure.
In contrast to DNA-based methods, our approach is correlated
with the level of bacterial susceptibility to the tested antibiotic
agent. If the bacteria are sensitive to the tested antimicrobial
concentration, the culture will exhibit a physiological response
according to its susceptibility, and this response can be quantified
at the mRNA level. However, if the bacteria are not sensitive to
the tested antimicrobial concentration, no stress will be imposed
on the culture; thus, no significant change in the expression of
the specific marker genes will be observed. Accordingly, at higher
antibiotics concentrations equal to or above the MIC of the
reduced susceptibility strain, a significant change in the markers’
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expression will be observed, thus enabling the determination of
the bacterial MIC value.
Antibiotic-responsive (induced or repressed) genes were
previously described for various antimicrobial agents; however,
these genes were not universal and not necessarily suitable
for MIC determination. The development of a molecular test
requires the identification of marker genes suitable for the
specific drug-bacterium combination and under the specific
(standard) exposure conditions. Therefore, we performed
DNA microarray analysis of the Y. pestis Kimberley53
virulent strain after exposure for various time periods to
several ciprofloxacin concentrations under standard CLSI test
guidelines. Ciprofloxacin was chosen because it is one of the
antibiotics of choice for treatment in Y. pestis exposure or
ongoing plague disease (Inglesby et al., 2000; Peterson et al.,
2010). We identified several SOS responsive genes that were
induced, and their levels of induction were correlated with
ciprofloxacin concentration. Some of those genes were also
induced to a greater extent as the exposure time increased
(Table 1). Eight genes (recN, dinI [YPO1232], recA, oraA, dinI
[YPO1586], b4058, dinP, and b4043, Table 1) of the 11 induced
genes identified following 2 h of exposure belong to the SOS
response gene family. We characterized four genes (recA, pla2,
recN, and dinI [YPO1232]) of the 11 induced genes for potential
use as markers for antimicrobial susceptibility determination
by the qRT-PCR method. The expression FC value of each
marker mRNA following exposure to 1× MIC antibiotic was
determined relative to the basal expression in the growth control
and was used for assignment of the threshold value. The markers’
threshold values were used to interpret the MIC values of
various Y. pestis strains and derivatives. The minimal antibiotic
concentration that resulted in marker gene expression equal to or
greater than its assigned threshold value was determined as the
molecular MIC value. This molecular MIC value was identical
to or differed by up to one 2-fold dilution from the standard
microdilution-derived MIC value and predicted identical
ciprofloxacin susceptibility categories of several derivatives,
representing a wide range of ciprofloxacin susceptibilities
(Figures 4–6). When evaluating a new susceptibility method,
both sensitive and resistant strains should be examined, and an
overall 1× MIC agreement of greater than 90% plus or minus
one double dilution of a standard CLSI-derived MIC should be
attained (Jorgensen and Ferraro, 2009). Our molecular assay is
well within the range of these guidelines.
An mRNA-based AST of various heterologous bacteria and
antibiotics was recently described (Barczak et al., 2012; Hou
et al., 2015). However, the experiments were performed using a
non-standard inoculum (OD600 of ∼1, which represents ∼10
9
CFU/ml). Inoculum concentration affects the MIC value (Figure
S1), and thus molecular susceptibility determination using a
non-standard inoculum size might be inaccurate. The reported
mRNA-based AST enables the determination of the category
FIGURE 7 | Schematic comparison of the steps and duration of the standard AST and the molecular AST for Y. pestis susceptibility determination.
*Isolation and enrichment steps are recommended by the CDC/WHO (Dennis et al., 1999). The AST conditions were guided by the CLSI recommendations (CLSI,
2015).
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of susceptibility only and not the MIC value, in contrast to
the method described here. In addition, the reported mRNA-
based AST was used to monitor alterations in gene expression
in cultures exposed to only one representative antibiotic
concentration (Barczak et al., 2012). We believe that molecular
AST should be conducted using a wider range of 2-fold
antibiotic dilutions in a microdilution-like format that includes
the category interpretation breakpoints, as we presented here.
This format, together with molecular mRNA marker expression
changes that correlate with the bacterial susceptibility level, will
enable the rapid determination of the category of susceptibility of
Y. pestis strains, regardless of their MIC value.
Here, we demonstrate that the duration of the AST can
be reduced by replacing the 24-h standard microdilution test
with a 7-h molecular AST that includes the following steps:
culture recovery (2 h), ciprofloxacin exposure (2 h), total
RNA purification (1 h) and qRT-PCR analysis of specific
mRNA markers (2 h; Figure 7). Automation of the total RNA
purification and qRT-PCR steps would make the assay simpler
and even faster.
Moreover, the duration of the overall susceptibility
determination process may be shortened by reducing not
only the AST assay but also the isolation and enrichment
preliminary steps. This alteration may be achieved using BIN, a
selective agar plate that can enable both Y. pestis selection and
efficient growth (Ber et al., 2003). Here, we used a 20- to 24-h
BIN-plated Y. pestis as the source for the molecular AST. Thus,
the usage of BIN in combination with the molecular AST may
reduce the overall required time for the standard CLSI-based
AST process, which can be up to 120 h for heterogeneous
environmental samples or ∼72 h for homogenous clinical
samples, to a 27- to 31-h protocol (Figure 7). Moreover, isolation
and enrichment from blood samples may be replaced by a 15-min
procedure of centrifugation using a vacutainer serum separation
tube (vacutainer SST), as we previously reported (Steinberger-
Levy et al., 2007) and may thus enable the antibiogram results
within 8 h.
A similar approach can be used to develop molecular assays
for additional antibiotics and for other slow-growing pathogenic
bacteria. We are currently using this novel molecular AST
approach to develop a similar assay for MIC and susceptibility
category determination of doxycycline for Y. pestis, an additional
recommended antibiotic for prophylaxis and treatment of plague.
AUTHOR CONTRIBUTIONS
Research project design: IS, OS, AZ, NA, AB, OI, and RB.
Experiments: IS, OS, AZ, NA, DG, MA, SM, and RB. Writing:
IS, OS, and RB.
FUNDING
This study was supported by the Israeli Institute of Biology
Research, Ness Ziona, Israel.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2016.00763
REFERENCES
Barczak, A. K., Gomez, J. E., Kaufmann, B. B., Hinson, E. R., Cosimi, L., Borowsky,
M. L., et al. (2012). RNA signatures allow rapid identification of pathogens
and antibiotic susceptibilities. Proc. Natl. Acad. Sci. U.S.A. 109, 6217–6222. doi:
10.1073/pnas.1119540109
Ben-Gurion, R., and Hertman, I. (1958). Bacteriocin-like material produced by
Pasteurella pestis. J. Gen. Microbiol. 19, 289–297.
Ber, R., Mamroud, E., Aftalion, M., Tidhar, A., Gur, D., Flashner, Y., et al. (2003).
Development of an improved selective agar medium for Isolation of Yersinia
pestis. Appl. Environ. Microbiol. 69, 5787–5792. doi: 10.1128/aem.69.10.5787-
5792.2003
Brazas, M. D., and Hancock, R. E. W. (2005). Ciprofloxacin induction of a
susceptibility determinant in Pseudomonas aeruginosa. Antimicrob. Agents
Chemother. 49, 3222–3227. doi: 10.1128/aac.49.8.3222-3227.2005
Burckhardt, I., and Zimmermann, S. (2011). Usingmatrix-assisted laser desorption
ionization-time of flight mass spectrometry to detect carbapenem resistance
within 1 to 2.5 hours. J. Clin. Microbiol. 49, 3321–3324. doi: 10.1128/jcm.
00287-11
Butler, T. (2013). Plague gives surprises in the first decade of the 21st century in
the United States and worldwide. Am. J. Trop. Med. Hyg. 89, 788–793. doi:
10.4269/ajtmh.13-0191
Cirz, R. T., Jones, M. B., Gingles, N. A., Minogue, T. D., Jarrahi, B., Peterson, S. N.,
et al. (2007). Complete and SOS-mediated response of Staphylococcus aureus to
the antibiotic ciprofloxacin. J. Bacteriol. 189, 531–539. doi: 10.1128/jb.01464-06
Cirz, R. T., O’Neill, B. M., Hammond, J. A., Head, S. R., and Romesberg, F. E.
(2006). Defining the Pseudomonas aeruginosa SOS response and its role in the
global response to the antibiotic ciprofloxacin. J. Bacteriol. 188, 7101–7110. doi:
10.1128/jb.00807-06
CLSI. (2015). M45 Methods for Antimicrobial Dilution and Disk Susceptibility
Testing of Infrequently Isolated or Fastidious Bacteria. Wayne, PA: Clinical and
Laboratories Standard Institute.
Dennis, D. T., Gage, K. L., Gratz, N. G., Poland, J. D., and Tikhomirov, E. (1999).
Plague Manual: Epidemiology, Distribution, Surveillance and Control. Geneva:
World Health Organization.
Dennis, D. T., and Hughes, J. M. (1997). Multidrug resistance in plague.
New Engl. J. Med. 337, 702–704. doi: 10.1056/NEJM1997090433
71010
Dörr, T., Lewis, K., and Vulic´, M. (2009). SOS response induces persistence
to fluoroquinolones in Escherichia coli. PLoS Genet. 5:e1000760. doi:
10.1371/journal.pgen.1000760
Flashner, Y., Mamroud, E., Tidhar, A., Ber, R., Aftalion, M., Gur, D., et al.
(2004). Generation of Yersinia pestis attenuated strains by signature-tagged
mutagenesis in search of novel vaccine candidates. Infect. Immun. 72, 908–915.
doi: 10.1128/iai.72.2.908-915.2004
Gage, K. L., and Kosoy, M. Y. (2005). Natural history of plague: perspectives
from more than a century of research. Ann. Rev. Entomol. 50, 505–528. doi:
10.1146/annurev.ento.50.071803.130337
Galimand, M., Carniel, E., and Courvalin, P. (2006). Resistance of Yersinia pestis
to antimicrobial agents. Antimicrob. Agents Chemother. 50, 3233–3236. doi:
10.1128/aac.00306-06
Gmuender, H., Kuratli, K., Di Padova, K., Gray, C. P., Keck, W., and Evers,
S. (2001). Gene expression changes triggered by exposure of Haemophilus
influenzae to novobiocin or ciprofloxacin: combined transcription and
translation analysis. Genome Res. 11, 28–42. doi: 10.1101/gr.157701
Hou, H.W., Bhattacharyya, R. P., Hung, D. T., and Han, J. (2015). Direct detection
and drug-resistance profiling of bacteremias using inertial microfluidics. Lab.
Chip. 15, 2297–2307. doi: 10.1039/c5lc00311c
Frontiers in Microbiology | www.frontiersin.org 12 May 2016 | Volume 7 | Article 763
Steinberger-Levy et al. Rapid Molecular Antibiotic Susceptibility Test
Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S.,
Eitzen, E., et al. (2000). Plague as a biological weapon: medical and public health
management. JAMA 283, 2281–2290. doi: 10.1001/jama.283.17.2281
Jepras, R. I., Paul, F. E., Pearson, S. C., and Wilkinson, M. J. (1997). Rapid
assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric
acid) trimethine oxonol and flow cytometry.Antimicrob. Agents Chemother. 41,
2001–2005.
Jorgensen, J. H., and Ferraro, M. J. (2009). Antimicrobial susceptibility testing: a
review of general principles and contemporary practices. Clin. Infect. Dis. 49,
1749–1755. doi: 10.1086/647952
Kaldalu, N., Mei, R., and Lewis, K. (2004). Killing by ampicillin and
ofloxacin induces overlapping changes in Escherichia coli transcription
profile. Antimicrob. Agents Chemother. 48, 890–896. doi: 10.1128/aac.48.3.890-
896.2004
Kinnunen, P., McNaughton, B. H., Albertson, T., Sinn, I., Mofakham, S.,
Elbez, R., et al. (2012). Self-assembled magnetic bead biosensor for
measuring bacterial growth and antimicrobial susceptibility testing. Small
(Weinheim an der Bergstrasse, Germany) 8, 2477–2482. doi: 10.1002/smll.2012
00110
Lindler, L. E., and Fan, W. (2003). Development of a 5′ nuclease assay to detect
ciprofloxacin resistant isolates of the biowarfare agent Yersinia pestis.Mol. Cell.
Probes 17, 41–47. doi: 10.1016/S0890-8508(02)00111-1
Lindler, L. E., Fan, W., and Jahan, N. (2001). Detection of ciprofloxacin-resistant
Yersinia pestis by fluorogenic PCR using the LightCycler. J. Clin. Microbiol. 39,
3649–3655. doi: 10.1128/JCM.39.10.3649-3655.2001
Louie, A., Brown, D. L., Liu, W., Kulawy, R. W., Deziel, M. R., and Drusano, G.
L. (2007a). In vitro infection model characterizing the effect of eﬄux pump
inhibition on prevention of resistance to levofloxacin and ciprofloxacin in
Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51, 3988–4000. doi:
10.1128/AAC.00391-07
Louie, A., Deziel, M. R., Liu, W., and Drusano, G. L. (2007b). Impact of resistance
selection and mutant growth fitness on the relative efficacies of Streptomycin
and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51,
2661–2667. doi: 10.1128/AAC.00073-07
Louie, A., Heine, H. S., VanScoy, B., Eichas, A., Files, K., Fikes, S., et al.
(2011a). Use of an in vitro pharmacodynamic model to derive a moxifloxacin
regimen that optimizes kill of Yersinia pestis and prevents emergence of
resistance. Antimicrob. Agents Chemother. 55, 822–830. doi: 10.1128/AAC.
00818-10
Louie, A., VanScoy, B., Liu, W., Kulawy, R., Brown, D., Heine, H. S., et al. (2011b).
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in
vitro pharmacodynamic model. Antimicrob. Agents Chemother. 55, 2623–2628.
doi: 10.1128/AAC.01374-10
Mulvey, M. C., Lemmon, M., Rotter, S., Lees, J., Einck, L., and Nacy, C. A. (2015).
Optimization of a nucleic acid-based reporter system to detectMycobacterium
tuberculosis antibiotic sensitivity. Antimicrob. Agents Chemother. 59, 407–413.
doi: 10.1128/aac.03135-14
Parkhill, J., Wren, B. W., Thomson, N. R., Titball, R. W., Holden, M. T.
G., Prentice, M. B., et al. (2001). Genome sequence of Yersinia pestis,
the causative agent of plague. Nature 413, 523–527. doi: 10.1038/350
97083
Peterson, J. W., Moen, S. T., Healy, D., Pawlik, J. E., Taormina, J., Hardcastle,
J., et al. (2010). Protection afforded by fluoroquinolones in animal models of
respiratory infections with Bacillus anthracis, Yersinia pestis, and Francisella
tularensis. Open Microbiol. J. 4, 34–46. doi: 10.2174/1874285801004010034
Pollitzer, R. (1960). A review of recent literature on plague. Bull.WHO 23, 313–400.
Pulido, M. R., García-Quintanilla, M., Martín-Peña, R., Cisneros, J. M., and
McConnell, M. J. (2013). Progress on the development of rapid methods for
antimicrobial susceptibility testing. J. Antimicrob. Chemother. 68, 2710–2717.
doi: 10.1093/jac/dkt253
Redgrave, L. S., Sutton, S. B., Webber, M. A., and Piddock, L. J. V.
(2014). Fluoroquinolone resistance: mechanisms, impact on bacteria,
and role in evolutionary success. Trends Microbiol. 22, 438–445. doi:
10.1016/j.tim.2014.04.007
Shaw, K. J., Miller, N., Liu, X., Lerner, D., Wan, J., Bittner, A., et al. (2003).
Comparison of the changes in global gene expression of Escherichia coli induced
by four bactericidal agents. J. Mol. Microbiol. Biotechnol. 5, 105–122. doi:
10.1159/000069981
Steinberger-Levy, I., Zahavy, E., Cohen, S., Flashner, Y., Mamroud, E., Aftalion, M.,
et al. (2007). Enrichment of Yersinia pestis from blood cultures enables rapid
antimicrobial susceptibility determination by flow cytometry. Adv. Exp. Med.
Biol. 603, 339–350. doi: 10.1007/978-0-387-72124-8_31
Tidhar, A., Flashner, Y., Cohen, S., Levi, Y., Zauberman, A., Gur, D., et al. (2009).
The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the
development of plague. PLoS ONE 4:e7023. doi: 10.1371/journal.pone.0007023
Udani, R. A., and Levy, S. B. (2006). MarA-like regulator of multidrug
resistance in Yersinia pestis. Antimicrob. Agents Chemother. 50, 2971–2975. doi:
10.1128/AAC.00015-06
Vagima, Y., Zauberman, A., Levy, Y., Gur, D., Tidhar, A., Aftalion, M., et al. (2015).
Circumventing Yersinia pestis virulence by early recruitment of neutrophils
to the lungs during pneumonic plague. PLoS Pathog 11:e1004893. doi:
10.1371/journal.ppat.1004893
van Belkum, A., and Dunne, W. M. (2013). Next-generation antimicrobial
susceptibility testing. J. Clin. Microbiol. 51, 2018–2024. doi: 10.1128/jcm.
00313-13
Waldeisen, J. R., Wang, T., Mitra, D., and Lee, L. P. (2011). A real-
time PCR antibiogram for drug-resistant sepsis. PLoS ONE 6:e28528. doi:
10.1371/journal.pone.0028528
Wiedemann, B., and Heisig, P. (1994). Mechanisms of quinolone resistance.
Infection 22, S73–S79. doi: 10.1007/bf01793570
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Steinberger-Levy, Shifman, Zvi, Ariel, Beth-Din, Israeli, Gur,
Aftalion, Maoz and Ber. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 13 May 2016 | Volume 7 | Article 763
